National trends in off-label use of atypical antipsychotics in children and adolescents in the United States
Open Access
- 1 June 2016
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medicine
- Vol. 95 (23), e3784
- https://doi.org/10.1097/md.0000000000003784
Abstract
The objectives of the study were as follows: to examine the national trend of pediatric atypical antipsychotic (AAP) use in the United States; to identify primary mental disorders associated with AAPs; to estimate the strength of independent associations between patient/provider characteristics and AAP use. Data are from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey. First, average AAP prescription rates among 4 and 18-year-old patients between 1993 and 2010 were estimated. Second, data from 2007 to 2010 were combined and analyzed to identify primary mental disorders related to AAP prescription. Third, a multivariate logistic regression model was developed having the presence of AAP prescription as the dependent variable and patient/provider characteristics as explanatory variables. Adjusted odds ratios (AORs) with associated 95% confidence intervals (CIs) were estimated. Outpatient visits including an AAP prescription among 4 to 18-year-old patients significantly increased between 1993 and 2010 in the United States, and over 65% of those visits did not have diagnoses for US Food and Drug Administration-approved AAP indications. During 2007 to 2010, the most common mental disorder was attention-deficit hyperactivity disorder, accounting for 24% of total pediatric AAP visits. Among visits with attention-deficit hyperactivity disorder diagnosis, those with Medicaid as payer (AOR 1.66, 95% CI 1.01–2.75), comorbid mental disorders (e.g., psychoses AOR 3.34, 95% CI 1.35–8.26), and multiple prescriptions (4 or more prescriptions AOR 4.48, 95% CI 2.08–9.64) were more likely to have an AAP prescription. The off-label use of AAPs in children and adolescents is prevalent in the United States. Our study raises questions about the potential misuse of AAPs in the population.Keywords
This publication has 21 references indexed in Scilit:
- Antipsychotics for Children and Young Adults: A Comparative Effectiveness ReviewPEDIATRICS, 2012
- The introduction of chlorpromazine in Belgium and the Netherlands (1951–1968); tango between old and new treatment featuresStudies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences, 2011
- Broadened Use Of Atypical Antipsychotics: Safety, Effectiveness, And Policy ChallengesHealth Affairs, 2009
- How often do children meet ICD-10/DSM-IV criteria of attention deficit-/hyperactivity disorder and hyperkinetic disorder? Parent-based prevalence rates in a national sample – results of the BELLA studyEuropean Child & Adolescent Psychiatry, 2008
- Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS StudySchizophrenia Research, 2007
- Atypical antipsychotics in the elderly with Parkinson disease and the “black box” warningNeurology, 2006
- Trends in Prescribing of Antipsychotic Medications for US ChildrenAcademic Pediatrics, 2006
- Effectiveness of Antipsychotic Drugs in Patients with Chronic SchizophreniaThe New England Journal of Medicine, 2005
- MedicaidThe New England Journal of Medicine, 2002
- THE DIAGNOSIS OF CHILDHOOD HYPERACTIVITY A U.S.‐U. K. CROSS‐NATIONAL STUDY OF DSM—III and ICD‐9Journal of Child Psychology and Psychiatry, 1988